Abstract
Glycosylation of the Fc moiety of a monoclonal antibody is a heterogeneous posttranslational process considered as a critical quality attribute of the purified drug substance due to its major impact on safety and efficacy (i.e., immunogenicity, CDC or ADCC effector functions, etc.).
Glycosylation should thus be addressed for batch-to-batch comparability and for drug substance characterization, in terms of identity and/or purity testing.
We present below a set of efficient, performing and complementary analytical tests that can be used alone or in combination, depending on the information needed and available laboratory instrumentation.
The results obtained using these techniques for “global” glycosylation profile, N-glycans profiling, monosaccharides, and sialic acids determination are presented for the Trastuzumab (Herceptin)-humanized mAb produced in CHO.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
CMC Biotech Working Group (2009) A-Mab case: a case study in bioprocess development. Version 2.1, pp 251–253.
Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, Goetsch L, Wurch T, Van Dorsselaer A, Corvaïa N (2008) Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 9:482–501
Raju TS (2008) Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 20:471–478
Gramer M, Eckblad J, Donahue R, Brown J, Shultz C, Vickerman K, Priem P, van den Bremer E, Gerritsen J, van Berkel P (2011) Modulation of antibody galactosylation through feeding of uridine, manganese chloride and galactose. Biotechnol Bioeng 108:1591–1602
Kaneko Y, Nimmerjahn F, Ravetch J (2006) Anti-inflammatory activity of immunoglobulin g resulting from Fc sialylation. Science 313:670–673
Ghaderi D, Taylor R, Padler-Karavani V, Diaz S, Varki A (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol 8:863–869
Goetze A, Liu Y, Zhang Z, Shah B, Lee E, Bondarenko P, Flynn G (2011) High mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21:949–959
Xie H, Chakraborty A, Ahn J, Yu Y, Dakshinamoorthy D, Gilar M, Chen W, Skilton SJ, Mazzeo J (2010) Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2:379–394
Anumula KR, Dhume ST (1998) High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid. Glycobiology 8:685–694
Gennaro LA, Salas-Solano O (2008) On-Line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies. Anal Chem 80:3838–3845
Saddic GN, Dhume ST, Anumula KR (2008) Carbohydrate composition analysis of glycoproteins by HPLC using highly fluorescent anthranilic acid (AA) tag. Methods Mol Biol 446:215–229
Chen FA, Dobashi TS, Evangelista RA (1998) Quantitative analysis of sugar constituents of glycoproteins by capillary electrophoresis. Glycobiology 8:1045–1052
Račaityte˙ K, Kiessig S, Kálmán F (2005) Application of capillary zone electrophoresis and reversed-phase high-performance liquid chromatography in the biopharmaceutical industry for the quantitative analysis of the monosaccharides released from a highly glycosylated therapeutic protein. J Chromatogr A 1079:354–365
Hara S, Takemori Y, Yamaguchi M, Nakamura M, Ohkura Y (1987) Fluorometric high-performance liquid chromatography of N-acetyl and N-glycolylneuraminic acids and its application to their microdetermination in human and animal sera, glycoproteins, and glycolipids. Anal Biochem 164:138–145
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this protocol
Cite this protocol
Delobel, A., Cantais, F., Catrain, A., Dereux, E., Van Vyncht, G. (2013). Therapeutic Antibody Glycosylation Analysis: A Contract Research Organization Perspective in the Frame of Batch Release or Comparability Support. In: Beck, A. (eds) Glycosylation Engineering of Biopharmaceuticals. Methods in Molecular Biology, vol 988. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-327-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-62703-327-5_8
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-326-8
Online ISBN: 978-1-62703-327-5
eBook Packages: Springer Protocols